<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38069140</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Mid-Regional Proadrenomedullin in COVID-19-May It Act as a Predictor of Prolonged Cardiovascular Complications?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">16821</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms242316821</ELocationID><Abstract><AbstractText>The rising prevalence of cardiovascular disease (CVD) and the impact of the SARS-CoV-2 pandemic have both led to increased mortality rates, affecting public health and the global economy. Therefore, it is essential to find accessible, non-invasive prognostic markers capable of identifying patients at high risk. One encouraging avenue of exploration is the potential of mid-regional proadrenomedullin (MR-proADM) as a biomarker in various health conditions, especially in the context of CVD and COVID-19. MR-proADM presents the ability to predict mortality, heart failure, and adverse outcomes in CVD, offering promise for improved risk assessment and treatment strategies. On the other hand, an elevated MR-proADM level is associated with disease severity and cytokine storms in patients with COVID-19, making it a predictive indicator for intensive care unit admissions and mortality rates. Moreover, MR-proADM may have relevance in long COVID, aiding in the risk assessment, triage, and monitoring of individuals at increased risk of developing prolonged cardiac issues. Our review explores the potential of MR-proADM as a predictor of enduring cardiovascular complications following COVID-19 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pietraszko</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5431-1400</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Hypertension, Medical University of Bialystok, 15-089 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorawski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2484-1579</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Hypertension, Medical University of Bialystok, 15-089 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bielecka</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Hypertension, Medical University of Bialystok, 15-089 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sielatycki</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Hypertension, Medical University of Bialystok, 15-089 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zbroch</LastName><ForeName>Edyta</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0121-3254</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Hypertension, Medical University of Bialystok, 15-089 Bialystok, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C088633">proadrenomedullin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>148498-78-6</RegistryNumber><NameOfSubstance UI="D053607">Adrenomedullin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053607" MajorTopicYN="N">Adrenomedullin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cardiovascular complications</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword><Keyword MajorTopicYN="N">mid-regional proadrenomedullin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38069140</ArticleId><ArticleId IdType="pmc">PMC10705931</ArticleId><ArticleId IdType="doi">10.3390/ijms242316821</ArticleId><ArticleId IdType="pii">ijms242316821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Y., Cao G.-Y., Jing W.-Z., Liu J., Liu M. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990&#x2212;2019: Findings from 2019 global burden of disease study. Eur. J. Prev. Cardiol. 2022;30:276&#x2013;286. doi: 10.1093/eurjpc/zwac285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwac285</ArticleId><ArticleId IdType="pubmed">36458973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rippe J.M. Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. Am. J. Lifestyle Med. 2019;13:204&#x2013;212. doi: 10.1177/1559827618812395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1559827618812395</ArticleId><ArticleId IdType="pmc">PMC6378495</ArticleId><ArticleId IdType="pubmed">30800027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtusiak J., Bagais W., Vang J., Roess A., Alemi F. Order of Occurrence of COVID-19 Symptoms. Qual. Manag. Health Care. 2023;32((Suppl. S1)):S29&#x2013;S34. doi: 10.1097/QMH.0000000000000397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QMH.0000000000000397</ArticleId><ArticleId IdType="pmc">PMC9811413</ArticleId><ArticleId IdType="pubmed">36579706</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Wang Y. The Clinical Characteristics and Risk Factors of Severe COVID-19, meta-analysis. Gerontology. 2021;67:255&#x2013;266. doi: 10.1159/000513400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513400</ArticleId><ArticleId IdType="pmc">PMC7900480</ArticleId><ArticleId IdType="pubmed">33406518</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura K., Kato J., Kawamoto M., Tanaka M., Chino N., Kangawa K., Eto T. The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma. Biochem. Biophys. Res. Commun. 1998;244:551&#x2013;555. doi: 10.1006/bbrc.1998.8310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1998.8310</ArticleId><ArticleId IdType="pubmed">9514956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinson J.P., Kapas S., Smith D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev. 2000;21:138&#x2013;167. doi: 10.1210/edrv.21.2.0396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/edrv.21.2.0396</ArticleId><ArticleId IdType="pubmed">10782362</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton D.C., Petrie M.C., Hillier C., Johnston F., McMurray J.J. The clinical relevance of adrenomedullin: A promising profile? Pharmacol. Ther. 2004;103:179&#x2013;201. doi: 10.1016/j.pharmthera.2004.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2004.07.002</ArticleId><ArticleId IdType="pubmed">15464589</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung B.M., Tang F. Adrenomedullin: Exciting new horizons. Recent Pat. Endocr. Metab. Immune Drug Discov. 2012;6:4&#x2013;17. doi: 10.2174/187221412799015263.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187221412799015263</ArticleId><ArticleId IdType="pubmed">22216776</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeran K., O&#x2019;Shea D., Upton P.D., Small C.J., Ghatei M.A., Byfield P.H., Bloom S.R. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: A pharmacokinetic study. J. Clin. Endocrinol. Metab. 1997;82:95&#x2013;100. doi: 10.1210/jc.82.1.95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.82.1.95</ArticleId><ArticleId IdType="pubmed">8989240</ArticleId></ArticleIdList></Reference><Reference><Citation>Elke G., Bloos F., Wilson D.C., Brunkhorst F.M., Briegel J., Reinhart K., Loeffler M., Kluge S., Nierhaus A., Jaschinski U., et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis&#x2013;A secondary analysis of a large randomised controlled trial. Crit. Care. 2018;22:79. doi: 10.1186/s13054-018-2001-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2001-5</ArticleId><ArticleId IdType="pmc">PMC5863464</ArticleId><ArticleId IdType="pubmed">29562917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaya N., Nishikimi T., Horio T., Yoshihara F., Kanazawa A., Matsuo H., Kangawa K., Mori H., Murakami S., Kitamura S., et al. Cardiovascular and renal effects of adrenomedullin in rats with heart failure. Am. J. Physiol. Integr. Comp. Physiol. 1999;276:R213&#x2013;R218. doi: 10.1152/ajpregu.1999.276.1.R213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.1999.276.1.R213</ArticleId><ArticleId IdType="pubmed">9887197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Zhang J., Wang X. Changes and cardiac protective effects of adrenomedullin during myocardial ischemia-reperfusion period. Zhonghua Yi Xue Za Zhi. 2000;80:261&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">11798767</ArticleId></ArticleIdList></Reference><Reference><Citation>Opgaard O.S., Hasbak P., de Vries R., Saxena P.R., Edvinsson L. Positive inotropy mediated via CGRP receptors in isolated human. Eur. J. Pharmacol. 2000;397:373&#x2013;382. doi: 10.1016/S0014-2999(00)00233-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(00)00233-8</ArticleId><ArticleId IdType="pubmed">10844137</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura H., Nagaya N., Itoh T., Okano I., Hino J., Mori K., Tsukamoto Y., Ishibashi-Ueda H., Miwa S., Tambara K., et al. Adrenomedullin Infusion Attenuates Myocardial Ischemia/Reperfusion Injury Through the Phosphatidylinositol 3-Kinase/Akt-Dependent Pathway. Circulation. 2004;109:242&#x2013;248. doi: 10.1161/01.CIR.0000109214.30211.7C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000109214.30211.7C</ArticleId><ArticleId IdType="pubmed">14691041</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclerc M., Brunette M.G. The paradoxical effect of adrenomedullin on na+ transport by the renal distal tubule luminal membrane. Mol. Cell Endocrinol. 2000;164:159&#x2013;167. doi: 10.1016/S0303-7207(00)00225-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0303-7207(00)00225-2</ArticleId><ArticleId IdType="pubmed">11026567</ArticleId></ArticleIdList></Reference><Reference><Citation>Owada A., Nonoguchi H., Terada Y., Marumo F., Tomita K., Ko S.B.H., Luo X., Hager H., Rojek A., Choi J.Y., et al. Microlocalization and effects of adrenomedullin in nephron segments and in mesangial cells of the rat. Am. J. Physiol. Physiol. 1997;272:F691&#x2013;F697. doi: 10.1152/ajprenal.1997.272.6.F691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.1997.272.6.F691</ArticleId><ArticleId IdType="pubmed">9227628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vari R.C., Adkins S.D., Samson W.K. Renal effects of adrenomedullin in the rat. Proc. Soc. Exp. Biol. Med. 1996;211:178&#x2013;183. doi: 10.3181/00379727-211-43959.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-211-43959</ArticleId><ArticleId IdType="pubmed">8599025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-Y., Wang F.-Z., Chang R., Wang Q., Liu S.-Y., Cheng Z.-X., Gao Q., Zhou H., Zhou Y.-B. Adrenomedullin Improves Hypertension and Vascular Remodeling partly through the Receptor-Mediated AMPK Pathway in Rats with Obesity-Related Hypertension. Int. J. Mol. Sci. 2023;24:3943. doi: 10.3390/ijms24043943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043943</ArticleId><ArticleId IdType="pmc">PMC9967515</ArticleId><ArticleId IdType="pubmed">36835355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato J., Kitamura K., Matsui E., Tanaka M., Ishizaka Y., Kita T., Kangawa K., Eto T. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens. Res. 1999;22:61&#x2013;65. doi: 10.1291/hypres.22.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1291/hypres.22.61</ArticleId><ArticleId IdType="pubmed">10221353</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliumi C., Cianci R., Celi M., Cerci S., Cotesta D., Petramala L., Fontana S., Letizia C. Plasma adrenomedullin concentrations in patients with renovascular or malignant hypertension. Minerva Cardioangiol. 2004;52:313&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C.M., Aarhus L.L., Heublein D.M., Sandberg S.M., Castrop H., H&#xf6;cherl K., Kurtz A., Schweda F., Todorov V., Wagner C., et al. Renal localization and actions of adrenomedullin: A natriuretic peptide. Pt 2Am. J. Physiol. Physiol. 1995;268:F657&#x2013;F663. doi: 10.1152/ajprenal.1995.268.4.F657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.1995.268.4.F657</ArticleId><ArticleId IdType="pubmed">7733322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama N., Kitamura K., Imamura T., Kato J., Koiwaya Y., Tsuji T., Kangawa K., Eto T. Molecular forms of circulating adrenomedullin in patients with congestive heart failure. J. Endocrinol. 1999;160:297&#x2013;303. doi: 10.1677/joe.0.1600297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/joe.0.1600297</ArticleId><ArticleId IdType="pubmed">9924200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.-M., Cheung B.M.Y., Leung R., Wang Q., Lai W.-H., Lau C.-P. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart. 2001;86:155&#x2013;160. doi: 10.1136/heart.86.2.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.86.2.155</ArticleId><ArticleId IdType="pmc">PMC1729865</ArticleId><ArticleId IdType="pubmed">11454830</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel A., Mueller C., Nowak R.M., Peacock W.F., Ponikowski P., Mockel M., Hogan C., Wu A.H., Richards M., Clopton P., et al. Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting with Acute Dyspnea: Results from the BACH (Biomarkers in Acute Heart Failure) Trial. J. Am. Coll. Cardiol. 2011;58:1057&#x2013;1067. doi: 10.1016/j.jacc.2011.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.06.006</ArticleId><ArticleId IdType="pubmed">21867843</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah R.V., Truong Q.A., Gaggin H.K., Pfannkuche J., Hartmann O., Januzzi J.L. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33:2197&#x2013;2205. doi: 10.1093/eurheartj/ehs136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs136</ArticleId><ArticleId IdType="pmc">PMC3432234</ArticleId><ArticleId IdType="pubmed">22645194</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;pinarov&#xe1; M., &#x160;pinar J., &#x160;pinarov&#xe1; L., Krej&#x10d;&#xed; J., Goldbergov&#xe1;-P&#xe1;vkov&#xe1; M., Pa&#x159;enica J., Ludka O., M&#xe1;lek F., O&#x161;&#x165;&#xe1;dal P., Bene&#x161;ov&#xe1; K., et al. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up&#x2014;Data from FAR NHL Registry. Medicina. 2022;58:1477. doi: 10.3390/medicina58101477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58101477</ArticleId><ArticleId IdType="pmc">PMC9611464</ArticleId><ArticleId IdType="pubmed">36295637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari S.S., Davies J.E., Struck J., Ng L.L. The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension. Metab. Clin. Exp. 2010;59:7&#x2013;13. doi: 10.1016/j.metabol.2009.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2009.06.019</ArticleId><ArticleId IdType="pubmed">19716143</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoto S., Argemi J., Di Costanzo R., Gomez J.J.G., Gonzales N.S., Basili S., Cangemi R., Abbate A., Locorriere L., Masini F., et al. Mid-Regional Pro-Adrenomedullin and N-Terminal Pro-B-Type Natriuretic Peptide Measurement: A Multimarker Approach to Diagnosis and Prognosis in Acute Heart Failure. J. Pers. Med. 2023;13:1155. doi: 10.3390/jpm13071155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm13071155</ArticleId><ArticleId IdType="pmc">PMC10381388</ArticleId><ArticleId IdType="pubmed">37511766</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitomi Y., Nishikimi T., Kojima S., Kuramochi M., Takishita S., Matsuoka H., Miyata A., Matsuo H., Kangawa K. Plasma levels of adrenomedullin in patients with acute myocardial infarction. Clin. Sci. 1998;94:135&#x2013;139. doi: 10.1042/cs0940135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs0940135</ArticleId><ArticleId IdType="pubmed">9536921</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S.Q., O&#x2019;Brien R.J., Struck J., Quinn P., Morgenthaler N., Squire I., Davies J., Bergmann A., Ng L.L. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: The lamp (leicester acute myocardial infarction peptide) study. J. Am. Coll. Cardiol. 2007;49:1525&#x2013;1532. doi: 10.1016/j.jacc.2006.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2006.12.038</ArticleId><ArticleId IdType="pubmed">17418290</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo M., Parenica J., Ganovska E., Pavlusova M., Mebazaa A. Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome. Int. J. Cardiol. Heart Vasc. 2019;22:174&#x2013;176. doi: 10.1016/j.ijcha.2019.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2019.02.011</ArticleId><ArticleId IdType="pmc">PMC6411493</ArticleId><ArticleId IdType="pubmed">30906846</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartopo A.B., Puspitawati I., Anggraeni V.Y. High Level of Mid-Regional Proadrenomedullin during ST-Segment Elevation Myocardial Infarction Is an Independent Predictor of Adverse Cardiac Events within 90-Day Follow-Up. Medicina. 2022;58:861. doi: 10.3390/medicina58070861.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58070861</ArticleId><ArticleId IdType="pmc">PMC9324579</ArticleId><ArticleId IdType="pubmed">35888580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzikas S., Keller T., Ojeda F.M., Zeller T., Wild P.S., Lubos E., Kunde J., Baldus S., Bickel C., Lackner K.J., et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart. 2012;99:388&#x2013;395. doi: 10.1136/heartjnl-2012-302956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2012-302956</ArticleId><ArticleId IdType="pubmed">23213173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M., Yoshida H., Makita S., Arakawa N., Niinuma H., Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997;95:1214&#x2013;1221. doi: 10.1161/01.CIR.95.5.1214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.95.5.1214</ArticleId><ArticleId IdType="pubmed">9054852</ArticleId></ArticleIdList></Reference><Reference><Citation>Szokodi I., Kinnunen P., Tavi P., Weckstr&#xf6;m M., T&#xf3;th M., Ruskoaho H. Evidence for CAMP-Independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 1998;97:1062&#x2013;1070. doi: 10.1161/01.CIR.97.11.1062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.97.11.1062</ArticleId><ArticleId IdType="pubmed">9531253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jougasaki M., Heublein D.M., Sandberg S.M., Burnett J.C. Attenuated natriuretic response to adrenomedullin in experimental heart failure. J. Card. Fail. 2001;7:75&#x2013;83. doi: 10.1054/jcaf.2001.23233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/jcaf.2001.23233</ArticleId><ArticleId IdType="pubmed">11264553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademaker M.T., Charles C.J., Espiner E.A., Nicholls M.G., Richards A.M. Long-term adrenomedullin administration in experimental heart failure. Hypertension. 2002;40:667&#x2013;672. doi: 10.1161/01.HYP.0000037132.90640.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000037132.90640.26</ArticleId><ArticleId IdType="pubmed">12411460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikimi T., Karasawa T., Inaba C., Ishimura K., Tadokoro K., Koshikawa S., Yoshihara F., Nagaya N., Sakio H., Kangawa K., et al. Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: A pilot study. Circ. J. 2009;73:892&#x2013;898. doi: 10.1253/circj.CJ-08-0487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-08-0487</ArticleId><ArticleId IdType="pubmed">19346663</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaya N., Goto Y., Satoh T., Sumida H., Kojima S., Miyatake K., Kangawa K. Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction. J. Cardiovasc. Pharmacol. 2002;39:754&#x2013;760. doi: 10.1097/00005344-200205000-00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005344-200205000-00017</ArticleId><ArticleId IdType="pubmed">11973420</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaya N., Nishikimi T., Uematsu M., Satoh T., Oya H., Kyotani S., Sakamaki F., Ueno K., Nakanishi N., Miyatake K., et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart. 2000;84:653&#x2013;658. doi: 10.1136/heart.84.6.653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.84.6.653</ArticleId><ArticleId IdType="pmc">PMC1729511</ArticleId><ArticleId IdType="pubmed">11083748</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S.-W., Ilyas I., Weng J.-P. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2023;44:695&#x2013;709. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandadeva D., Young B.E., Stephens B.Y., Grotle A.-K., Skow R.J., Middleton A.J., Haseltine F.P., Fadel P.J. Blunted peripheral but not cerebral vasodilator function in young otherwise healthy adults with persistent symptoms following COVID-19. Am. J. Physiol. Heart Circ. Physiol. 2021;321:H479&#x2013;H484. doi: 10.1152/ajpheart.00368.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00368.2021</ArticleId><ArticleId IdType="pmc">PMC8384473</ArticleId><ArticleId IdType="pubmed">34296966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratchford S.M., Stickford J.L., Province V.M., Stute N., Augenreich M.A., Koontz L.K., Bobo L.K., Stickford A.S. Vascular alterations among young adults with SARS-CoV-2. Am. J. Physiol. Circ. Physiol. 2021;320:H404&#x2013;H410. doi: 10.1152/ajpheart.00897.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00897.2020</ArticleId><ArticleId IdType="pmc">PMC8083172</ArticleId><ArticleId IdType="pubmed">33306450</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Bluemke D.A., L&#xfc;scher T.F., Neubauer S. Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 2022;43:1157&#x2013;1172. doi: 10.1093/eurheartj/ehac031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac031</ArticleId><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro L., Zaccone V., Falsetti L., Ruggieri V., Danese M., Miro C., Di Giorgio A., Nesci A., D&#x2019;alessandro A., Moroncini G., et al. Role of Endothelium in Cardiovascular Sequelae of Long COVID. Biomedicines. 2023;11:2239. doi: 10.3390/biomedicines11082239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11082239</ArticleId><ArticleId IdType="pmc">PMC10452509</ArticleId><ArticleId IdType="pubmed">37626735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda S., Nishio K., Minamino N., Kubo A., Akai Y., Kangawa K., Matsuo H., Fujimura Y., Yoshioka A., Masui K., et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am. J. Respir. Crit. Care Med. 1999;160:132&#x2013;136. doi: 10.1164/ajrccm.160.1.9810006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.160.1.9810006</ArticleId><ArticleId IdType="pubmed">10390390</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s C., Andaluz-Ojeda D., Cicuendez R., Nogales L., Mart&#xed;n S., Martin-Fernandez M., Almansa R., Calvo D., Esteban-Velasco M.C., Vaquero-Roncero L.M., et al. MR-proADM to detect specific types of organ failure in infection. Eur. J. Clin. Investig. 2020;50:e13246. doi: 10.1111/eci.13246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13246</ArticleId><ArticleId IdType="pubmed">32307701</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;nal U., Valenzuela-S&#xe1;nchez F., Vandana K.E., Rello J. Mid-Regional Pro-Adrenomedullin (MR-proADM) as a biomarker for sepsis and septic shock: Narrative review. Healthcare. 2018;6:110. doi: 10.3390/healthcare6030110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare6030110</ArticleId><ArticleId IdType="pmc">PMC6164535</ArticleId><ArticleId IdType="pubmed">30177659</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino R., Struck J., Maisel A.S., Magrini L., Bergmann A., Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit. Care. 2014;18:34. doi: 10.1186/cc13731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc13731</ArticleId><ArticleId IdType="pmc">PMC4056312</ArticleId><ArticleId IdType="pubmed">24533868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa A., Geven C., Hollinger A., Wittebole X., Chousterman B.G., Blet A., Gayat E., Hartmann O., Scigalla P., Struck J., et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: The prospective observational multinational adrenomedullin and outcome in sepsis and septic shock-1 (adrenoss-1) study. Crit. Care. 2018;22:354. doi: 10.1186/s13054-018-2243-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2243-2</ArticleId><ArticleId IdType="pmc">PMC6305573</ArticleId><ArticleId IdType="pubmed">30583748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg O.H.M., Lengquist M., Sp&#xe5;ngfors M., Annborn M., Bergmann D., Schulte J., Levin H., Melander O., Frigyesi A., Friberg H. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit. Care. 2020;24:636. doi: 10.1186/s13054-020-03351-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03351-1</ArticleId><ArticleId IdType="pmc">PMC7641835</ArticleId><ArticleId IdType="pubmed">33148300</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsson P., Fredriksson A., Tung C., Friberg H., Frigyesi A. Plasma bioactive adrenomedullin on intensive care unit admission is associated with acute respiratory distress syndrome: An observational study. Intensiv. Care Med. Exp. 2023;11:10. doi: 10.1186/s40635-023-00494-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-023-00494-7</ArticleId><ArticleId IdType="pmc">PMC9981258</ArticleId><ArticleId IdType="pubmed">36864354</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Liu L., He W., Shang N., Li J., Qin Z., Du X. Circulating mid-regional proadrenomedullin is a predictor of mortality in patients with COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 2023;23:305. doi: 10.1186/s12879-023-08275-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08275-z</ArticleId><ArticleId IdType="pmc">PMC10165584</ArticleId><ArticleId IdType="pubmed">37158819</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lier D., Deniau B., Santos K., Hartmann O., Dudoignon E., Depret F., Plaud B., Laterre P.-F., Mebazaa A., Pickkers P. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: A prospective international multicentre study. ERJ Open Res. 2022;9:00342&#x2013;2022. doi: 10.1183/23120541.00342-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00342-2022</ArticleId><ArticleId IdType="pmc">PMC9571166</ArticleId><ArticleId IdType="pubmed">36628268</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrich W.C., R&#xfc;egger K., Dusemund F., Schuetz P., Arici B., Litke A., Blum C.A., Bossart R., Regez K., Schild U., et al. Biomarker-enhanced triage in respiratory infections: A proof-of-concept feasibility trial. Eur. Respir. J. 2013;42:1064&#x2013;1075. doi: 10.1183/09031936.00113612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00113612</ArticleId><ArticleId IdType="pmc">PMC3787815</ArticleId><ArticleId IdType="pubmed">23349444</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oers J.A., Kluiters Y., Bons J.A., de Jongh M., Pouwels S., Ramnarain D., de Lange D.W., de Grooth H.-J., Girbes A.R. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study. J. Crit. Care. 2021;66:173&#x2013;180. doi: 10.1016/j.jcrc.2021.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2021.07.017</ArticleId><ArticleId IdType="pmc">PMC8289696</ArticleId><ArticleId IdType="pubmed">34340901</ArticleId></ArticleIdList></Reference><Reference><Citation>de Guadiana-Romualdo L.G., Mart&#xed;nez M.M., Mulero M.D.R., Esteban-Torrella P., Olivo M.H., Garc&#xed;a M.J.A., Campos-Rodr&#xed;guez V., Sancho-Rodr&#xed;guez N., Mart&#xed;nez M.G., Alcaraz A., et al. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Int. J. Infect. Dis. 2021;111:211&#x2013;218. doi: 10.1016/j.ijid.2021.08.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.08.058</ArticleId><ArticleId IdType="pmc">PMC8400460</ArticleId><ArticleId IdType="pubmed">34461254</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti I., Spinelli D., Callegari T., Bonometti R., Molinaro E., Novara E., Cassinari M., Frino C., Guaschino R., Boverio R., et al. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: The experience of a single, italian Center. Eur. Rev. Med. Pharmacol. Sci. 2021;25:1743&#x2013;1751. doi: 10.26355/eurrev_202102_24885.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202102_24885</ArticleId><ArticleId IdType="pubmed">33629344</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G., Sales G., Balzani E., Lombardo D., Giaccone A., Cant&#xf9; G., D&#x2019;Antonio G., Rumbolo F., Corcione S., Simonetti U., et al. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study. Front. Med. 2023;10:1122367. doi: 10.3389/fmed.2023.1122367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1122367</ArticleId><ArticleId IdType="pmc">PMC10080079</ArticleId><ArticleId IdType="pubmed">37035317</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore N., Williams R., Mori M., Bertolusso B., Vernet G., Lynch J., Philipson P., Ledgerwood T., Kidd S.P., Thomas C., et al. Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting. J. Clin. Pathol. 2022;76:400&#x2013;406. doi: 10.1136/jclinpath-2021-207750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2021-207750</ArticleId><ArticleId IdType="pubmed">34996755</ArticleId></ArticleIdList></Reference><Reference><Citation>de Guadiana-Romualdo L.G., Nieves M.D.C., Mulero M.D.R., Alises I.C., Olivo M.H., Fern&#xe1;ndez W.T., Morales M.G., Jim&#xe9;nez C.B., Albaladejo-Ot&#xf3;n M.D., Ovalle H.F., et al. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur. J. Clin. Investig. 2021;51:e13511. doi: 10.1111/eci.13511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13511</ArticleId><ArticleId IdType="pmc">PMC7995076</ArticleId><ArticleId IdType="pubmed">33569769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertmer C., Morelli A., Rehberg S., Lange M., Hucklenbruch C., Van Aken H., Booke M., Westphal M. Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia. Br. J. Anaesth. 2007;99:830&#x2013;836. doi: 10.1093/bja/aem295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aem295</ArticleId><ArticleId IdType="pubmed">17962242</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh T., Obata H., Murakami S., Hamada K., Kangawa K., Kimura H., Nagaya N., Kach J., Sandbo N., Sethakorn N., et al. Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats. Am. J. Physiol. Cell Mol. Physiol. 2007;293:L446&#x2013;L452. doi: 10.1152/ajplung.00412.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00412.2005</ArticleId><ArticleId IdType="pubmed">17557801</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmesfeld-Wollbr&#xfc;ck B., Brell B., D&#xe1;vid I., Dorenberg M., Adolphs J., Schmeck B., Suttorp N., Hippenstiel S. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. 2007;33:703&#x2013;710. doi: 10.1007/s00134-007-0561-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-007-0561-y</ArticleId><ArticleId IdType="pubmed">17318497</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmesfeld-Wollbr&#xfc;ck B., Brell B., zu Dohna C., Dorenberg M., Hocke A.C., Martens H., Klar J., Suttorp N., Hippenstiel S. Adrenomedullin reduces intestinal epithelial permeability in vivo and in vitro. Am. J. Physiol. Liver Physiol. 2009;297:G43&#x2013;G51. doi: 10.1152/ajpgi.90532.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90532.2008</ArticleId><ArticleId IdType="pubmed">19423749</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal M., Stubbe H., Bone H.-G., Daudel F., Vocke S., Van Aken H., Booke M. Hemodynamic effects of exogenous adrenomedullin in healthy and endotoxemic sheep. Biochem. Biophys. Res. Commun. 2002;296:134&#x2013;138. doi: 10.1016/S0006-291X(02)00821-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)00821-5</ArticleId><ArticleId IdType="pubmed">12147239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kita T., Kitamura K. Adrenomedullin Therapy in Moderate to Severe COVID-19. Biomedicines. 2022;10:533. doi: 10.3390/biomedicines10030533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10030533</ArticleId><ArticleId IdType="pmc">PMC8945653</ArticleId><ArticleId IdType="pubmed">35327335</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.-H., Zhao L., Yang X.-C., Wang P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): A systematic review and meta-analysis. Rev. Cardiovasc. Med. 2021;22:159&#x2013;165. doi: 10.31083/j.rcm.2021.01.238.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm.2021.01.238</ArticleId><ArticleId IdType="pubmed">33792257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole C., Stefanou E., Karvelas N., Schizas D., Toutouzas K.P. Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review. Cardiovasc. Drugs Ther. 2023;20:1&#x2013;16. doi: 10.1007/s10557-023-07465-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-023-07465-w</ArticleId><ArticleId IdType="pmc">PMC10199303</ArticleId><ArticleId IdType="pubmed">37209261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.C.E., Ali K., Connell D., Mordi I.R., George J., Lang E.M., Lang C.C. COVID-19-associated cardiovascular complications. Diseases. 2021;9:47. doi: 10.3390/diseases9030047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases9030047</ArticleId><ArticleId IdType="pmc">PMC8293160</ArticleId><ArticleId IdType="pubmed">34209705</ArticleId></ArticleIdList></Reference><Reference><Citation>Giurgi-Oncu C., Tudoran C., Pop G.N., Bredicean C., Pescariu S.A., Giurgiuca A., Tudoran M. Cardiovascular Abnormalities and Mental Health Difficulties Result in a Reduced Quality of Life in the Post-Acute COVID-19 Syndrome. Brain Sci. 2021;11:1456. doi: 10.3390/brainsci11111456.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11111456</ArticleId><ArticleId IdType="pmc">PMC8615893</ArticleId><ArticleId IdType="pubmed">34827455</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya F., Yener&#xe7;a&#x11f; F.N.T., Kaya A., &#x15e;ener Y.Z., Ba&#x11f;c&#x131; A. Long term effects of mild severity COVID19 on right ventricular functions. Int. J. Cardiovasc. Imaging. 2021;37:3451&#x2013;3457. doi: 10.1007/s10554-021-02340-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-021-02340-x</ArticleId><ArticleId IdType="pmc">PMC8274467</ArticleId><ArticleId IdType="pubmed">34251551</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudoran C., Tudoran M., Pop G.N., Giurgi-Oncu C., Cut T.G., Lazureanu V.E., Oancea C., Parv F., Ciocarlie T., Bende F. Associations between the Severity of the Post-Acute COVID-19 Syndrome and Echocardiographic Abnormalities in Previously Healthy Outpatients Following Infection with SARS-CoV-2. Biology. 2021;10:469. doi: 10.3390/biology10060469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology10060469</ArticleId><ArticleId IdType="pmc">PMC8226755</ArticleId><ArticleId IdType="pubmed">34073342</ArticleId></ArticleIdList></Reference><Reference><Citation>Standl E., Schnell O. Heart failure outcomes and COVID-19. Diabetes Res. Clin. Pract. 2021;175:108794. doi: 10.1016/j.diabres.2021.108794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2021.108794</ArticleId><ArticleId IdType="pmc">PMC8020602</ArticleId><ArticleId IdType="pubmed">33831494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391. doi: 10.1136/bmjopen-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewek J., Jatczak-Pawlik I., Maciejewski M., Jankowski P., Banach M. COVID-19 and cardiovascular complications&#x2014;The preliminary results of the LATE-COVID study. Arch. Med. Sci. 2021;17:818&#x2013;822. doi: 10.5114/aoms/134211.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms/134211</ArticleId><ArticleId IdType="pmc">PMC8130484</ArticleId><ArticleId IdType="pubmed">34025853</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S., Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: A case series of 20 patients. Immunol. Res. 2021;69:205&#x2013;211. doi: 10.1007/s12026-021-09185-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09185-5</ArticleId><ArticleId IdType="pmc">PMC8009458</ArticleId><ArticleId IdType="pubmed">33786700</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;court C., Buxton M., Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudoran C., Tudoran M., Cut T.G., Lazureanu V.E., Oancea C., Marinescu A.R., Pescariu S.A., Pop G.N., Bende F. Evolution of echocardiographic abnormalities identified in previously healthy individuals recovering from COVID-19. J. Pers. Med. 2022;12:46. doi: 10.3390/jpm12010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12010046</ArticleId><ArticleId IdType="pmc">PMC8778114</ArticleId><ArticleId IdType="pubmed">35055360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sar&#x131;&#xe7;am E., Dursun A.D., Sar&#x131;y&#x131;ld&#x131;z G.T., Can N., Bozkurt E., G&#xf6;n&#xfc;ll&#xfc; U., Basay N., T&#xfc;rkmen M., Denli A., &#xdc;nl&#xfc; M. Laboratory and imaging evaluation of cardiac involvement in patients with post-acute COVID-19. Int. J. Gen. Med. 2021;14:4977&#x2013;4985. doi: 10.2147/IJGM.S321156.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S321156</ArticleId><ArticleId IdType="pmc">PMC8412825</ArticleId><ArticleId IdType="pubmed">34511982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund L.C., Hallas J., Nielsen H., Koch A., Mogensen S.H., Brun N.C., Christiansen C.F., Thomsen R.W., Potteg&#xe5;rd A. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: A Danish population-based cohort study. Lancet Infect. Dis. 2021;21:1373&#x2013;1382. doi: 10.1016/S1473-3099(21)00211-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre-Mu&#xf1;iz M.M., Arias &#xc1;., Mata-V&#xe1;zquez E., Mart&#xed;n-Toledano M., L&#xf3;pez-Larramona G., Ruiz-Chicote A.M., Nieto-Sandoval B., Lucendo A.J. Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge. J. Clin. Med. 2021;10:2945. doi: 10.3390/jcm10132945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10132945</ArticleId><ArticleId IdType="pmc">PMC8269002</ArticleId><ArticleId IdType="pubmed">34209085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Post-COVID syndrome in individuals admitted to hospital with COVID-19: Retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody W.E., Liu B., Mahmoud-Elsayed H.M., Senior J., Lalla S.S., Khan-Kheil A.M., Brown S., Saif A., Moss A., Bradlow W.M., et al. Persisting adverse ventricular remodeling in COVID-19 survivors: A longitudinal echocardiographic study. J. Am. Soc. Echocardiogr. 2021;34:562&#x2013;566. doi: 10.1016/j.echo.2021.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2021.01.020</ArticleId><ArticleId IdType="pmc">PMC8008825</ArticleId><ArticleId IdType="pubmed">33539950</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitbart P., Koch A., Schmidt M., Magedanz A., Lindhoff-Last E., Voigtl&#xe4;nder T., Schmermund A., Mehta R.H., Eggebrecht H. Clinical and cardiac magnetic resonance findings in post-COVID patients referred for suspected myocarditis. Clin. Res. Cardiol. 2021;110:1832&#x2013;1840. doi: 10.1007/s00392-021-01929-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-021-01929-5</ArticleId><ArticleId IdType="pmc">PMC8390029</ArticleId><ArticleId IdType="pubmed">34448040</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A.K., Imperatore G., Rolka D.B., Lundeen E., Rutkowski R.E., Jackson S.L., He S., Kuklina E.V., Park S., Pavkov M.E. Risk of Cardiovascular Disease After COVID-19 Diagnosis Among Adults with and Without Diabetes. J. Am. Heart. Assoc. 2023;12:e029696. doi: 10.1161/JAHA.123.029696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.029696</ArticleId><ArticleId IdType="pmc">PMC10356070</ArticleId><ArticleId IdType="pubmed">37382101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan E.Y.F., Mathur S., Zhang R., Yan V.K.C., Lai F., Chui C., Li X., Wong C.K.H., Yiu K.H., Chan E.W.Y., et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: A prospective cohort in UK Biobank. Br. J. Gen. Pract. 2023;73:bjgp23X734121. doi: 10.3399/bjgp23X734121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp23X734121</ArticleId><ArticleId IdType="pubmed">36652991</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Rhermoul F.-Z., Fedorowski A., Eardley P., Taraborrelli P., Panagopoulos D., Sutton R., Lim P.B., Dani M. Autoimmunity in Long COVID and POTS. Oxf. Open Immunol. 2023;4:iqad002. doi: 10.1093/oxfimm/iqad002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqad002</ArticleId><ArticleId IdType="pmc">PMC10224806</ArticleId><ArticleId IdType="pubmed">37255928</ArticleId></ArticleIdList></Reference><Reference><Citation>Votto M., Castagnoli R., Marseglia G.L., Licari A., Brambilla I. COVID-19 and autoimmune diseases: Is there a connection? Curr. Opin. Allergy Clin. Immunol. 2023;23:185&#x2013;192. doi: 10.1097/ACI.0000000000000888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACI.0000000000000888</ArticleId><ArticleId IdType="pubmed">36728317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremonesi M., Felicetta A., Cannata F., Serio S., van Beek J.J., Bombace S., My I., Zanon V., Catalano C., Papadopoulou V., et al. Long COVID-19 Cardiac Complications Are Associated with Autoimmunity to Cardiac Self-Antigens Sufficient to Cause Cardiac Dysfunction. Circulation. 2023;148:504&#x2013;507. doi: 10.1161/CIRCULATIONAHA.122.062672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.062672</ArticleId><ArticleId IdType="pubmed">37549204</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiral J., Seghatchian J. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes. Transfus. Apher. Sci. 2022;62:103625. doi: 10.1016/j.transci.2022.103625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2022.103625</ArticleId><ArticleId IdType="pmc">PMC9757887</ArticleId><ArticleId IdType="pubmed">36585276</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallek M., Adorjan K., Behrends U., Ertl G., Suttorp N., Lehmann C. Post-COVID Syndrome. Dtsch. Arztebl. Int. 2023;120:48&#x2013;55. doi: 10.3238/arztebl.m2022.0409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.m2022.0409</ArticleId><ArticleId IdType="pmc">PMC10060997</ArticleId><ArticleId IdType="pubmed">36633452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>